Quick answer
What do published mouse studies report about MOTS-c and age-related decline? A 2021 study reported that MOTS-c enhanced physical performance in young (2 months), middle-aged (12 months) and old (22 months) mice, and that intermittent MOTS-c exposure (three times a week) begun late in life (23.5 months) increased physical capacity and healthspan. The 2015 discovery paper reported that exposure prevented age-dependent and high-fat-diet-induced insulin resistance. This article lays out what each study measured, how the experiments were built and where the evidence ends. It summarizes published animal work only. MOTS-c is supplied for laboratory research use only.
The question these studies ask
Aging research in rodents asks whether a manipulation changes how fast function declines: grip strength, running capacity, gait, glucose handling and body composition. For a peptide encoded in mitochondrial DNA, the natural hypothesis is that levels or activity of the peptide change with age or exercise and that adding it back could influence age-related functional decline. Two papers carry most of the weight, and a review of mitochondrial-derived peptides in aging pulls the wider evidence together.[1] The MOTS-c research overview covers the compound's profile; this page is limited to the aged-animal evidence.
The two anchor studies side by side
| Feature | Lee 2015[2] | Reynolds 2021[3] |
|---|---|---|
| Main claim | MOTS-c regulates insulin sensitivity and metabolic homeostasis; target organ appears to be skeletal muscle | MOTS-c enhances physical performance across ages and is exercise-induced |
| Ages or states | Age-dependent and high-fat-diet-induced insulin resistance | Young (2 mo), middle-age (12 mo), old (22 mo) mice |
| Exposure | MOTS-c exposure in mice | Including late-life (23.5 mo) intermittent exposure, 3x/week |
| Readouts named in abstract | Insulin resistance; diet-induced obesity | Physical performance; nuclear gene regulation; skeletal muscle metabolism; myoblast adaptation to metabolic stress |
| Mechanistic statement | Folate cycle and de novo purine biosynthesis inhibited, leading to AMPK activation | Regulates nuclear genes related to metabolism and proteostasis |
| Human data in the same paper | None stated in the abstract | Exercise induces endogenous MOTS-c expression in skeletal muscle and in circulation |
Both abstracts frame the finding as regulation by a mitochondrial-encoded factor. Reynolds and colleagues concluded that aging is regulated by genes encoded in both the mitochondrial and the nuclear genomes.[3]
The 2021 study in detail
The Reynolds study reported that MOTS-c could significantly enhance physical performance in mice at three ages, which is a design choice worth noting: testing at 2, 12 and 22 months separates an effect that appears only in old animals from one that is present throughout life. It also reported that MOTS-c regulates nuclear genes, including those related to metabolism and proteostasis, regulates skeletal muscle metabolism, and regulates myoblast adaptation to metabolic stress. Late-life initiation at 23.5 months with intermittent exposure three times a week was reported to increase physical capacity and healthspan in mice. In humans, exercise was reported to induce endogenous MOTS-c expression in skeletal muscle and in circulation.[3] A review of mitochondrial-derived peptides and exercise summarizes the evidence that acute high-intensity exercise in humans can increase MOTS-c and humanin concentrations in muscle and plasma, and speculates about the mechanisms.[4]
What the abstract does not tell a reader is the specific dose, the vehicle and the exact test battery, and those are the details to read in the full paper before attempting a comparison.
Ovariectomy and hormone-loss models
Aging is not the only model of metabolic decline in the literature. In ovariectomized mice, MOTS-c exposure was reported to prevent ovariectomy-induced obesity and insulin resistance, to increase brown fat activation, to reduce fat accumulation and inflammatory invasion in white adipose tissue, and to activate the AMPK pathway; an AMPK blocker attenuated the effect on adipocyte lipid metabolism.[5] Another ovariectomy study reported that MOTS-c at 5 mg/kg once a day for 12 weeks significantly alleviated bone loss by micro-CT and inhibited RANKL-induced osteoclast differentiation, with AMPK phosphorylation increased and the AMPK inhibitor compound C partially abrogating the effect on osteoclastogenesis.[6] These are separate disease models, but they share the AMPK mechanism, which is why they appear together in aging-adjacent reviews.
Model summary
| Model | Species | Reported outcome | Source |
|---|---|---|---|
| Age-dependent and high-fat-diet insulin resistance | Mouse | Prevented by MOTS-c exposure | Lee 2015[2] |
| Physical performance at 2, 12 and 22 months | Mouse | Enhanced | Reynolds 2021[3] |
| Late-life intermittent exposure from 23.5 months | Mouse | Physical capacity and healthspan increased | Reynolds 2021[3] |
| Ovariectomy-induced obesity and insulin resistance | Mouse | Prevented; brown fat activity sustained | Lu 2019[5] |
| Ovariectomy-induced bone loss | Mouse | Alleviated by micro-CT | Ming 2016[6] |
| Senescent fibroblasts | Human cells | Endogenous peptide levels measured; more mitochondria, higher respiration | Kim 2018[7] |
Each row is a separate experiment with its own controls and endpoints, so the table lists outcomes without implying that they add up to a single effect.
Cellular aging: senescence data
In primary human fibroblasts made senescent by replicative exhaustion, doxorubicin or hydrogen peroxide, researchers measured mitochondrial number, respiration, mtDNA methylation and the levels of humanin, MOTS-c, SHLP2 and SHLP6.[7] Senescent cells showed more mitochondria and higher respiration, with variable changes in mtDNA methylation. This is a cell model and it concerns endogenous peptide levels rather than the effect of adding a peptide; it is useful mainly as a reminder that "age-related" can mean different things at the cellular and organismal levels.
Limits of the evidence
- Few anchor studies. Among the sources reviewed here, the aged-animal functional data rest mainly on one group's 2021 paper, with supporting model studies from others.
- Different readouts. Physical performance, insulin sensitivity, bone loss and adipose function are separate endpoints; improvement in one does not imply the others.
- Intermittent exposure was specific. The late-life design used a defined three-times-weekly schedule; other schedules were not shown by the abstract.
- Association in humans. The human finding is that exercise induces endogenous MOTS-c, and a cross-sectional study of 225 subjects reported lower serum mitochondrial-derived peptide levels in diabetes subjects.[8] Both describe association.
- Species. All exposure data cited are from mice.
Planning a replication-minded experiment
A group wanting to evaluate these findings in its own aging model should pre-specify age groups (young, middle, old), a defined functional battery (for example grip strength and treadmill capacity), randomization and blinding, and a vehicle arm exposed on the same schedule. Peptide material should be documented: lot, purity, COA and storage. The stock arithmetic is: concentration = mass (mg) ÷ 2,175 g/mol ÷ volume (mL) in mmol/mL; use the calculator. A lot-specific COA (lot ARC-MO10-007) is linked from the MOTS-c product page, and the identity and purity fields are explained in MOTS-c purity testing.
Research-use statement
This article reports published animal and cell studies. All material discussed here is supplied for laboratory research use only; not for human or animal consumption, and not a drug, food or cosmetic.
Related reading
- MOTS-c research overview: the pillar guide
- MOTS-c product page: size, purity, lot COA and storage line
- What is MOTS-c peptide?
- MOTS-c vs other mitochondrial-derived peptides
- MOTS-c AMPK pathway research background
- MOTS-c nuclear translocation research background
- MOTS-c reconstitution and storage
- MOTS-c purity testing
- Browse all research compounds
Frequently asked questions
At what ages was MOTS-c tested in the 2021 mouse study?
Young (2 months), middle-aged (12 months) and old (22 months) mice, plus a late-life (23.5 months) intermittent exposure design.[3]
What exposure schedule was used in the late-life experiment?
Intermittent exposure three times a week, started at 23.5 months, per the abstract.[3]
What did the 2015 paper report about age and diet?
That MOTS-c exposure prevented age-dependent and high-fat-diet-induced insulin resistance and diet-induced obesity in mice.[2]
What happens to MOTS-c with exercise?
Exercise was reported to induce endogenous MOTS-c expression in human skeletal muscle and circulation.[3][4]
Which mechanism recurs across the studies?
AMPK activation, reported in the original paper and in two ovariectomy models.[2][5][6]
Were ovariectomized mice studied?
Yes. One study reported prevention of obesity and insulin resistance, and another reported reduced bone loss.[5][6]
What does a senescence study add?
It shows how endogenous MOTS-c and related peptides and mitochondrial function change in senescent human fibroblasts, but it is not a exposure study.[7]
Do these studies cover people?
No exposure data in people are cited. The human findings are about endogenous levels and association.[3][8]
What details should be read in the full paper?
Dose, vehicle, route, schedule and the exact test battery.
Is MOTS-c intended for people or animals?
No. It is supplied for laboratory research use only; not for human or animal consumption.
Related reading: MOTS-c and AMPK: Assays, Tool Compounds and Controls, MOTS-c, Exercise and Skeletal Muscle: Published Data, MOTS-c, Glucose Metabolism and Insulin Resistance Assays.
References
- Kim SJ, et al. Mitochondrial-derived peptides in aging and age-related diseases. GeroScience. 2021. doi:10.1007/s11357-020-00262-5 PMID: 32910336
- Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015. doi:10.1016/j.cmet.2015.02.009 PMID: 25738459
- Reynolds JC, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021. doi:10.1038/s41467-020-20790-0 PMID: 33473109
- Woodhead JST, et al. Mitochondrial-derived peptides and exercise. Biochim Biophys Acta Gen Subj. 2021. doi:10.1016/j.bbagen.2021.130011 PMID: 34520826
- Lu H, et al. MOTS-c peptide regulates adipose homeostasis to prevent ovariectomy-induced metabolic dysfunction. J Mol Med. 2019. doi:10.1007/s00109-018-01738-w PMID: 30725119
- Ming GF, et al. Mitochondria related peptide MOTS-c suppresses ovariectomy-induced bone loss via AMPK activation. Biochem Biophys Res Commun. 2016. doi:10.1016/j.bbrc.2016.05.135 PMID: 27237975
- Kim SJ, et al. Mitochondrial peptides modulate mitochondrial function during cellular senescence. Aging. 2018. doi:10.18632/aging.101463 PMID: 29886458
- Ramanjaneya M, et al. Mitochondrial-derived peptides are down regulated in diabetes subjects. Front Endocrinol. 2019. doi:10.3389/fendo.2019.00331 PMID: 31214116
